Oral Cancer: Types, Warning Signs and Diagnosis

A small ulcer on the lateral tongue, a painless palatal swelling and an extraction socket that keeps enlarging can all bring a patient to a dental clinic. They raise different questions about tissue of origin and the next investigation. The dentist’s first task is to record the exact site, identify what makes the finding suspicious and arrange assessment. Histopathology establishes the type of tumour in most cases. Staging describes how far a confirmed cancer has spread.

What counts as oral cavity cancer

The oral cavity includes the mucosal lips, inner cheeks, gingiva and alveolar ridges, floor of the mouth, hard palate, retromolar trigone and mobile tongue. The tongue base, palatine tonsils and soft palate belong to the oropharynx. A phrase such as “posterior tongue cancer” can obscure a boundary that changes staging and the interpretation of HPV testing. On the lip, record whether the lesion begins on the mucosal surface, dry vermilion or skin. An imprecise label such as “lower-lip cancer” leaves out information the pathology and oncology teams need.

A lesion can cross these boundaries. Its epicentre is the site where it appears to originate. Describe the presumed epicentre and every involved structure, then indicate any uncertainty. A hard-palate lesion that extends onto the soft palate and a soft-palate lesion that extends forward can occupy some of the same visible area. The team establishes the likely primary site through examination, imaging and pathology.

Which malignancies can present in the mouth

Oral squamous cell carcinoma (OSCC) is the predominant malignancy of the oral mucosa. It arises from squamous epithelium. The current WHO classification lists oral SCC, verrucous carcinoma and carcinoma cuniculatum under squamous cell carcinomas of the oral cavity and mobile tongue. Histopathology reporting also distinguishes variants such as spindle cell and basaloid SCC. Variants and tumour grade require tissue assessment. A warty, flat or ulcerated surface cannot establish the subtype.

These groups can overlap clinically. A palatal mass can arise in minor salivary tissue, from a dental infection, from an adjacent anatomical region or from another process. Location helps organise the differential and plan the referral. It seldom settles the diagnosis by itself.

Burden in India and worldwide

The IARC Global Cancer Observatory estimated 205,878 new cases and 86,307 deaths in India in 2024 for the combined lip and oral cavity category. The corresponding global estimates were 452,205 new cases and 194,108 deaths. Both fact sheets cover both sexes and all ages. These estimates use ICD-10 C00–C06 and include more than one histologic type. The release has a separate C09–C10 oropharynx category, and its statistical groupings differ from clinical staging boundaries. For example, C01 denotes base of tongue and falls within C00–C06.

Read the measure before quoting a number. A count helps describe how many people were affected. An age-standardised rate is more useful for comparing populations with different age structures, provided the same standard and site definitions are used. A national estimate cannot describe the exposure mix or diagnostic delays in a particular district. Deaths in a calendar year also include people diagnosed in earlier years, so the ratio of deaths to new cases is different from a survival estimate.

Risk factors to ask about in the dental history

Tobacco, areca nut and alcohol

Ask separately about smoked tobacco, smokeless tobacco, areca nut, and alcohol. Record the name and composition of the preparation where possible. Terms such as paan, gutka or supari can describe products or habits with different ingredients. Ask how often the product is used, for how long, and where it is held in the mouth. Areca nut and betel quid without added tobacco can increase oral cancer risk. A patient who reports no tobacco use may still have substantial areca exposure.

Smoking and alcohol can interact in oral carcinogenesis. Record both histories even when one exposure appears to explain the presentation. In practice, risk-factor history changes the level of concern and provides a basis for cessation support. A concerning lesion warrants assessment in a person without these exposures as well. Sun exposure belongs in the history of chronic vermilion changes, especially when actinic cheilitis or a lip malignancy is being considered.

HPV has different implications by site

High-risk HPV has an established role in a subset of oropharyngeal squamous cell carcinomas, particularly at tonsillar sites and the tongue base. CAP recommends testing in defined oropharyngeal settings. CAP advises against routine high-risk HPV testing for prognostic purposes in primary oral cavity SCC. A p16 result also needs interpretation within the correct anatomical and testing context. Record the primary site before interpreting a discussion of HPV-related prognosis.

Potentially malignant disorders, dysplasia and invasion

An oral potentially malignant disorder (OPMD) is a clinical condition associated with increased risk of oral cancer. Oral leukoplakia, erythroplakia, proliferative verrucous leukoplakia and oral submucous fibrosis are examples. They differ in presentation and risk. Oral leukoplakia is a clinical diagnosis reached after excluding other definable causes of a predominantly white plaque. A white lesion that reflects friction, an infection or oral hairy leukoplakia needs its own diagnosis and management.

Epithelial dysplasia is a microscopic finding. A report may describe architectural and cellular changes and assign a grade. Invasive carcinoma is diagnosed when malignant epithelial cells invade underlying tissue. A lesion can contain a mixture of histologic findings, and a sampled area may differ from an adjacent red, indurated or ulcerated area. If the clinical appearance and biopsy report do not agree, discuss sample adequacy and the need for further assessment with the specialist.

Take particular care when comparing studies of OPMDs. Cancer already present at the initial biopsy and cancer that develops later during follow-up are different outcomes. Risk estimates depend on the condition, case definitions, biopsy findings and follow-up. Explain to the patient what is known about their lesion, what remains uncertain and when the next assessment is due.

Warning signs and what to record

An unexplained ulcer, a persistent red or red-and-white patch, a firm margin or an enlarging lump merits careful assessment. Some early lesions cause little pain. More extensive disease may affect tongue movement, swallowing, speech or mouth opening. A cervical lump can accompany a small or hard-to-see primary. Ask when the patient first noticed the finding, how it has changed and whether there are new functional symptoms.

These findings can occur in benign disease. Their value lies in identifying where routine dental explanations fit poorly. Progressive tooth mobility with an irregular gingival mass deserves a broader workup than mobility well explained by established periodontal findings. New chin numbness without a clear dental or procedural explanation should be investigated in context. Record positive and pertinent negative findings in the referral.

Chairside examination and referral

Examine the lesion in the context of the whole mouth

Update the medical, dental and social history. Ask about prior cancer, immune suppression, previous biopsies and relevant exposures. Under good lighting, inspect the lips, cheeks, gingiva, palate, floor of mouth and tongue surfaces, then complete the relevant extraoral examination. Use palpation where appropriate to assess consistency, tenderness and fixation. Include the neck and evaluate function when symptoms warrant it. A focal lesion can be the reason for the visit while other sites still need examination.

Record the side, subsite, size and surrounding landmarks. For a tongue lesion, specify dorsal, lateral or ventral surface and mobile tongue versus base when discernible. Note whether it crosses the midline. Describe an ulcer, plaque or mass in ordinary clinical terms and record any palpable induration. A dated image with consent and a scale can support documentation. A clear written description helps even if a photograph cannot be obtained.

Choose between prompt referral and short reassessment

A lesion that is already suspicious warrants prompt biopsy by a suitably trained clinician or referral to the relevant specialist. Use the suspected-cancer pathway available in the local setting. For a lesion that appears likely to be traumatic and is suitable for observation, address the cause and give a definite review appointment. The ADA’s 2026 chairside guide advises biopsy or referral when a mucosal abnormality is still unresolved beyond 10 to 14 days after initial evaluation without a definitive diagnosis or treatment plan. Findings that raise suspicion at the initial visit justify acting sooner.

NICE NG12 gives a UK suspected-cancer referral criterion for unexplained oral ulceration lasting longer than three weeks and includes additional routes for oral lumps and red or red-and-white patches. It is a jurisdiction-specific pathway. In India, refer through the applicable local dental, oral medicine, maxillofacial or head and neck oncology service. Include the observed reason for concern and confirm that the patient knows how to attend. Agree on who will follow up if the appointment is missed.

Two contrasting chairside presentations

A firm lateral-tongue ulcer. An adult reports an ulcer that has enlarged despite removing an apparent irritant. Examination finds a firm margin and a red component. Document the mobile tongue subsite, measurements, symptoms and neck findings. Arrange prompt referral or appropriate biopsy. A history of irritation does not account for continued enlargement and induration by itself.

A recent ulcer with a clear mechanical cause. A patient has a small ulcer in contact with the new sharp edge of a fractured restoration. Examination supports a low-risk traumatic explanation. Address the irritant within scope, document the lesion, give a specific review date and explain which changes should prompt earlier contact. Persistent or progressive change needs reassessment and possible biopsy or referral.

What establishes the diagnosis

A specialist chooses the sampling approach based on the site, lesion extent and differential. An incisional biopsy can provide a representative sample of a larger or suspicious lesion, and more than one mapped site may be appropriate when appearances differ. The request should convey the duration, exact subsite, key clinical findings, exposure history and any previous pathology. If a deeper process or another lineage such as lymphoma is suspected, early coordination helps the team plan the specimen and ancillary tests.

Histopathology can establish whether the sample shows a benign process, dysplasia or invasive cancer, and identify the type when adequate. An adjunctive test answers a narrower question. The ADA’s 2026 guidance advises against routinely using oral cytology to determine whether a lesion needs biopsy or referral. It provides a conditional fallback when biopsy is not possible, advisable or indicated, and advises prompt biopsy or referral for a persistent or progressive lesion despite negative cytology. The guideline advises against using toluidine blue and light-based adjuncts to decide whether biopsy or referral is needed and limits salivary adjuncts to research settings.

Imaging serves a different purpose. CT or MRI can help define deep local extent, bone involvement or nodal disease as appropriate. Ultrasound and image-guided sampling may help evaluate selected neck nodes. The clinical team may use additional imaging for staging, depending on the diagnosis and suspected extent. A destructive radiographic finding alone cannot identify a tumour’s lineage.

How staging and treatment decisions follow

For oral cavity carcinoma, TNM records features of the primary tumour, regional nodes and distant disease. Clinical staging uses findings available before definitive treatment. Pathological staging adds information from surgical specimens when available. For oral cavity squamous cell carcinoma, depth of invasion contributes to the primary tumour category. The pathologist measures it from the reconstructed level of the adjacent mucosal basement membrane to the deepest point of invasion. Nodal findings, including extranodal extension where applicable, also matter. The 2026 AJCC staging table retains the eighth edition for oral cavity cancer. Selected other sites have moved to Version 9, so check the applicable chapter and diagnosis date.

A multidisciplinary team balances tumour control with expected effects on speech, swallowing and appearance. Surgery is an important option in many resectable oral cavity SCCs. Planning may include management of the neck, reconstruction, and discussion of radiotherapy or concurrent chemoradiotherapy based on the case and pathology. Recurrent, metastatic and non-squamous malignancies may call for other pathways. The general dentist helps coordinate the dental timeline and shares findings that could affect treatment or rehabilitation.

Dental care through treatment and follow-up

Before head and neck radiotherapy or systemic treatment, review current dental disease, oral hygiene and anticipated oncology plans with the team. Record baseline findings and coordinate needed treatment. During and after therapy, follow-up may include assessment of mucositis, oral infection, dry mouth, caries risk, restricted opening and function. Before a later invasive dental procedure, obtain relevant radiation and treatment history and discuss site-specific risk with the appropriate team.

Prognosis depends on the primary site, histology, stage, nodal findings, treatment and patient factors. A population statistic is most useful when it identifies the registry, diagnosis years, sites and stage group. Surveillance also considers recurrence, new primary disease and functional recovery. Ask about new or progressive symptoms and maintain clear channels for reassessment.

Prevention and the role of the dental visit

Discuss cessation support for tobacco and areca use in a way that identifies the patient’s actual products and barriers to stopping. The dental examination is an opportunity to assess mucosal change and explain what warrants a return visit. Evidence from organised visual screening in Kerala concerns a defined programme and population, with important findings in higher-risk groups. Screening results and the diagnostic assessment of a symptomatic patient answer different questions. A suspicious finding requires a plan for definitive assessment and follow-through.